Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial

MLA

Ständer, Sonja, et al. “Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.” American Journal of Clinical Dermatology, vol. 24, Dec. 2022, pp. 97–107. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cbff8fe5570e6ed3bdcc5e9e4cc12de5&authtype=sso&custid=ns315887.

APA

Ständer, S., Kwatra, S. G., Silverberg, J. I., Simpson, E. L., Thyssen, J. P., Yosipovitch, G., Zhang, F., Cameron, M. C., Cella, R. R., Valdez, H., DiBonaventura, M., & Feeney, C. (2022). Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial. American Journal of Clinical Dermatology, 24, 97–107.

Chicago

Ständer, Sonja, Shawn G. Kwatra, Jonathan I. Silverberg, Eric L. Simpson, Jacob P. Thyssen, Gil Yosipovitch, Fan Zhang, et al. 2022. “Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.” American Journal of Clinical Dermatology 24 (December): 97–107. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cbff8fe5570e6ed3bdcc5e9e4cc12de5&authtype=sso&custid=ns315887.